A Phase 1b Study of TAK-659 in Combination With NKTR-214 in Patients With Advanced Non-Hodgkin Lymphoma
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2019
Price : $35 *
At a glance
- Drugs Bempegaldesleukin (Primary) ; Mivavotinib (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Takeda
- 10 Jul 2019 Status changed from recruiting to withdrawn prior to enrolment.
- 10 Jul 2019 Planned initiation date changed from 13 May 2019 to 3 Apr 2019.
- 27 May 2019 Status changed from not yet recruiting to recruiting.